Revolutionizing Drug Discovery: SandboxAQ Integrates AI Models with Anthropic’s Claude
The journey to discover new drugs is notoriously lengthy and costly, often spanning over a decade and requiring billions of dollars, with many potential candidates failing to reach the market. While numerous AI startups have aimed to streamline this process by enhancing the tools available to researchers, SandboxAQ has identified a different bottleneck: the user interface.
In a strategic move, SandboxAQ has partnered with Anthropic to embed its advanced scientific AI models directly into Claude, Anthropic’s conversational AI platform. This integration places sophisticated drug discovery and materials science tools behind an intuitive conversational interface, eliminating the need for specialized computing infrastructure or extensive technical expertise.
Established approximately five years ago as a spinout from Alphabet, SandboxAQ boasts Eric Schmidt, former CEO of Google, as its chairman. The company has successfully raised over $950 million from investors and has diversified its operations to include ventures like a cybersecurity business.
A standout feature of SandboxAQ is its development of large quantitative models (LQMs). These proprietary models are physics-grounded, meaning they are constructed based on the fundamental principles of the physical world rather than solely on patterns derived from text data. LQMs are capable of performing quantum chemistry calculations and simulating both molecular dynamics and microkinetics—the study of chemical reactions at the molecular level. This capability allows researchers to predict how candidate molecules are likely to behave before conducting laboratory experiments.
Trained on real-world lab data and scientific equations, LQMs are AI models engineered for the quantitative economy, a $50+ trillion sector spanning biopharma, financial services, energy, and advanced materials, the company stated in a recent news release. This statement underscores SandboxAQ’s ambition to transform industries through AI, moving beyond the development of chatbots or code assistants.
While other well-funded companies like Chai Discovery and Isomorphic Labs have concentrated on advancing scientific models, SandboxAQ is prioritizing accessibility. For the first time, we have a frontier [quantitative] model on a frontier LLM that someone can access in natural language, said Nadia Harhen, SandboxAQ’s general manager of AI simulation, in an interview with TechCrunch. Previously, users of SandboxAQ’s LQMs needed to provide their own digital infrastructure to run the models, which posed a significant barrier to entry.
SandboxAQ’s clientele primarily includes computational scientists, research scientists, and experimentalists working in large pharmaceutical or industrial companies. These professionals are often in search of new materials that can be developed into marketable products. Our customers come to us because they’ve tried all the other software out there, and the complexity of their problem is such that it didn’t work or didn’t yield positive results for them when that translation went to take place in the real world, Harhen explained.
By integrating its LQMs with Anthropic’s Claude, SandboxAQ is democratizing access to advanced drug discovery tools, enabling a broader range of researchers to leverage AI in their work without the need for extensive computing resources or specialized knowledge. This collaboration represents a significant step forward in making the drug discovery process more efficient and accessible.
